• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Lorglumide Sodium

Product ID L5769
Cas No.
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $92.80 In stock
25 mg $203.70 In stock
100 mg $651.80 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Lorglumide is an antagonist at cholestocystokinin (CCK) receptors; it exhibits antacid, anti-ulcerative, gastrointestinal motility modulating, and anticancer activities. Lorglumide decreases gastrointestinal motility and gastric secretion and is clinically used to treat ulcers, irritable bowel syndrome, constipation, and dyspepsia. Lorglumide also inhibits proliferation of colon cancer cells.

Product Info

Purity

≥98%

Formula

C22H31Cl2N2O4Na

Formula Wt.

481.39

Chemical Name

(±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentyl- amino)-5-oxopentanoic acid sodium salt

IUPAC Name

sodium;4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate

Synonym

Lorglumide sodium salt

Solubility

Soluble in methanol or water.

Appearance

White Powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

L5769 MSDS PDF

Info Sheet

L5769 Info Sheet PDF

References

González-Puga C, García-Navarro A, Escames G, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res. 2005 Oct;39(3):243-50. PMID: 16150104.

Makovec F, Bani M, Cereda R, et al. Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Pharmacol Res Commun. 1987 Jan;19(1):41-51. PMID: 3575382.

Makovec F, Bani M, Cereda R, et al. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. PMID: 3440035.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only